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Summary The concentration of cellular fibronectin (cFN) containing the extra domain A (EDA) was
measured in 479 plasma and 300 serum samples from healthy blood donors by a competitive enzyme
immunoassay (EIA). Serum and plasma samples contained low concentrations of EDAcFN. The mean
concentration of EDAcFN was higher in plasma (2.46mgl-') than in serum (0.30mg1-'). No significant
differences between sexes or age groups were found. The EDAcFN concentrations were also measured in 120
patients with various malignancies. The mean values in serum were 4.28 mg I-', 2.01 mg 1' and 5.18 mg 1-1 in
patients with digestive tract malignancies, breast cancer and a group of miscellaneous cancers respectively. In
plasma. the corresponding values were 12.26mg1I. 4.38mgl1' and 11.12mgl ' respectively. The serum
EDAcFN concentration was higher than the 97.5th percentile level of healthy blood donors in 86% of patients
with digestive tract and in 76% with miscellaneous malignancies. In patients with breast cancer 60% had
elevated levels of EDAcFN. The corresponding figures for plasma samples in patients with digestive tract and
miscellaneous malignancies were 7900 and 71% respectively. In patients with breast cancer only 30% had
elevated plasma levels of EDAcFN. The mean values in serum and plasma of 20 patients with benign diseases
were below the cut-off levels. Consistent with the EIA results, Western blotting revealed increased amounts of
EDAcFN in blood samples from cancer patients. Pregnancy did not affect the EDAcFN concentration. The
mean values in 20 pregnant women were below the cut-off levels.
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FNs are adhesive glycoproteins that have variable primary
structures owing to cell type-specific splicing of FN precursor
mRNA. FNs can be divided into two major groups: plasma
(p) and cellular (c) forms. cFNs differ from pFN in having
the so called extra domain (ED) sequences A or B in the
molecule (Schwarzbauer, 1991). Hepatocytes produce pFN.
while cFNs are produced locally (Tamkun and Hynes, 1983).
However, plasma also contains small quantities of cFN (Var-
tio et al., 1987). All FNs can be found in soluble form and
also deposited in pericellular matrices.
Numerous studies have shown that FNs have a role in
various biological phenomena, such as cell adhesion, mobility
and differentiation (Yamada et al., 1985). Determining the
concentration of FN in plasma appears useful in evaluating
the status of the mononuclear phagocytic system (Mosher,
1980; Stathakis et al., 1981). In many studies total FN in
plasma and other body fluids has been evaluated as a marker
for cancer or other diseases (Parsons et al., 1979a,b; Webb
and Linn, 1980; Stathakis et al., 1981; Choate and Mosher,
1983; Siri et al., 1984; Boccardo et al., 1986; Ruelland et al.,
1988; Katayama et al., 1991). For this purpose various quan-
titative methods for measuring FN concentration have been
developed.
Only recently, have specific antibodies made it possible to
study the cellular form of FN containing the EDA sequence.
In immunohistochemical stainings, EDAcFN has been shown
to be abundantly present in certain developing basement
membranes and in reactive adult tissues (Vartio et al., 1987;
Virtanen et al., 1988; Gould et al., 1990; Laitinen et al.,
1991). EDAcFN also showed a strong expression in the
stroma of all studied carcinomas (Vartio et al., 1987). We
recently described a quantitative enzyme immunoassay based
on monoclonal antibody (MAb) DH1, detecting the
EDAcFN (YlItupa et al., 1993). In this study expression of
EDAcFN in plasma and serum of healthy blood donors is
described in detail, and the upper limits of normals in serum
and plasma are determined. A prelminary evaluation of the
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expression of EDAcFN in serum and plasma from cancer
patients is reported. A more detailed evaluation of EDAcFN
in various forms of cancer is the subject of a separate report.
Materials and methdKs
Serun andplasma samples
Three hundred serum and 479 plasma samples were collected
from healthy blood donors in the Finnish Red Cross Blood
Transfusion Service. Preparative serum and plasma samples
were obtained from 140 patients with malignant and benign
diseases. Samples from 120 patients with malignant tumours
were divided into three groups: 43 patients with digestive
tract cancer (ten colorectal, 13 pancreatic, three liver, three
duodenal, three stomach and two oesophageal cancers and
nine gastrointestinal carcinomas of unknown origin), 60
patients with breast cancer and 17 patients with miscel-
laneous malignancies (ten bladder, three lung, one renal cell
carcinoma, two prostate carcinoma and one eye carcinoma).
The group of benign diseases comprised ten subjects with gall
stone diseases and ten with benign breast diseases. Plasma
samples were also obtained from 20 pregnant women. Blood
was collected by venepuncture into sodium EDTA (final
concentration 4 mmol I-') or anticoagulated with 0.1 volume
of trisodium citrate. Plasma was separated by centrifugation
at 1400g at room temperature. Blood for serum samples was
allowed to coagulate at +4°C for 1 h before separation by
centrifugation. Samples were stored at - 70°C and thawed at
+4C for 12 h before the assay. This study was carried out
with ethical committee approval.
Isolation ofFNs
FNs from sera and plasma of healthy blood donors and
patients with malignancies were isolated by affinity chrom-
atography on gelatin-Sepharose 4B (Pharmacia, Uppsala,
Sweden), as described by Engvall and Ruoslahti (1977). cFN,
produced by A8387 fibrosarcoma cells, was isolated by the
same method from collected spent growth medium of theC fi n, a new tmour narker
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cells, seeded after trypsinisation in serum-free medium to
avoid co-purification of serum FN. Protein concentrations
were measured according to Lowry et at. (1951) using bovine
serum albumin as standard. The purity of the preparations
was checked by electrophoresis.
Competitive enzyme imnunoassay for EDAcFN
The concentration of EDAcFN in serum and plasma samples
was measured by a competitive enzyme immunoassay as
described previously (Ylatupa et al., 1993). In short, micro-
titration strips coated with cFN were washed. A 50 IL sample
was first incubated with 50iLl of peroxidase-conjugated DH1
antibody against EDAcFN separately on non-coated strips
and then transferred to the coated strips. After incubation at
+37C for 1 h the strips were washed and substrate incuba-
tion was allowed to proceed for 30 min. After stopping the
reaction, absorbance was measured at 450 mm.
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Electrophoresis and Western blotting
MAbs BF12 (Biohit Oy, Helsinki, Finland), which reacts
with all FNs, and DHI (Biohit Oy), which reacts exclusively
with EDAcFN, have been characterised previously (Vartio et
al., 1987). For immunoblotting, sodium dodecylsulphate
polyacrylamide gel electrophoresis (SDS-PAGE; Laemmli,
1970) was performed using 6.5% vertical slab gels under
reducing conditions. After electrophoresis, the gels were
either protein stained (Fairbanks et al., 1971) or subjected
to Western blotting (Towbin et al., 1979) by trans-
ferring SDS-PAGE-separated polypeptides onto nitrocel-
lulose sheets. Immunoreactions were detected by peroxidase-
coupled MAbs DH1 or BF12.
Statistical analysis
The Mann-Whitney U-test (the two-tailed test) was used to
obtain the probability (P) values of the data measured. Pro-
bability values less than 0.05 were considered significant.
Receiver operating charactenrstic (ROC) curves were con-
structed by calculating the true-positive fraction and false-
positive fraction of EDAcFN in plasma and serum at several
cut-off points.
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cFN in plasma and serun ofhealthy blood donors
The EDAcFN concentration in plasma and serum samples
was determined using competitive EDAcFN EIA as des-
cribed previously (Ylatupa et al., 1993). The coefficient of
variation (CV) for measurement of both inter-assay and
intra-assay standards (n = 6) and samples (n =4) was less
than 10%. The intra-assay CV varied between 2.0% and
7.0% and the inter-assay CV ranged between 4.0% and
8.0%.
In plasma from healthy blood donors, the mean concentra-
tion of EDAcFN was 2.46± 1.99 mgl'. The mean serum
concentration was 0.30 ± 0.51 mg 1- In men, the mean con-
centrations of EDAcFN in plasma and serum were 2.65 ±
2.09 mg I` (n = 244) and 0.32 ± 0.56 mg 1` (n = 169) respec-
tively, and in women 2.08 ± 1.83 mg 1-l (n = 235) and 0.28 ±
0.43 mg 1' (n = 131) respectively. The differences between
sexes were not statistically significant. In similar fashion,
significant differences were not apparent between groups of
subjects aged 18-35 years (plasma 1.77± 1.74mg 1-l, n=
161; serum 0.31 ± 0.55mgl-', n=97), 36-50 years (plasma
2.45± 1.88 mgl-', n= 159; serum 0.28±0.46mg 1-', n=
128) and 51-65 years (plasma 2.88 ± 2.06 mg I-', n = 159;
serum 0.32 ± 0.55 mg -', n = 79). The distribution in plasma
and serum according to sex and age is shown in Figures la
and b. The cut-off levels in plasma and serum based on the
97.5th percentile were 6.5 mg Il and 1.1 mg l- ' respectively.
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Figwe 1 The concentration of EDAcFN (mg -') in plasma (a)
and serum (b) samples from healthy blood donors according to
age and sex.
EDAcFN in plasma ofpregnant women
The mean concentration of EDAcFN in plasma samples of
pregnant women was 4.41 ± 1.81 mgl-', which was higher
(P<0.05) than that of healthy blood donors (2.46 ± 1.99
mg I-) but did not exceed the cut-off level.
EDAcFN in plasma ofpatients wtih benign diseases
In plasma from 20 patients with benign diseases the mean
concentration of EDAcFN was 2.62 ± 2.00 mg 1'. The mean
serum concentration was 0.53 ± 0.69 mg 1'. All plasma sam-
ples had lower values than the cut-off level of 6.50 mg -',
but in serum six (30%) of the samples exceeded the cut-off
level of l.lOmgl-' (Figure 2).
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Tabl I Frequency and mean level of elevated EDAcFN concen-
trations (mgl-') in serum and plasma of patients with various
malignant diseases
n % Mean
cFN in PLASMA
Digestive tract cancer 34 43 79 12.26
Colorectal 6/10 60 9.33
Pancreatic 11'13 85 12.14
Liver 3/3 100 16.9
Duodenal 3/3 100 20.1
Stomach 3/3 100 14.65
Oesophagus 2/2 100 15.75
Gastrointestinal cancer of unknown onrgin 6/9 67 9.94
Miscellaneous malignancies 12/17 71 11.12
Bladder 8/10 80 11.82
Lung 2/3 67 11.36
Others 3,4 75 9.23
Breast cancer 18/60 30 4.38
cFN in SERUM
Digestive tract cancer 37 43 86 4.28
Colorectal 8/10 80 3.19
Pancreatic 10/13 77 3.94
Liver 3/3 100 6.75
Duodenal 33 100 8.86
Stomach 3/3 100 8.36
Oesophagus 2,2 100 1.2
Gastrointestinal cancer of unknown onrgin 8/9 89 2.98
Miscellaneous malignancies 13,17 76 5.18
Bladder 8110 80 6.39
Lung 2/3 67 5.13
Others 34 75 2.16
Breast cancer 36/60 60 2.00
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Fugwe 2 The concentration of EDAcFN (mg 1') in plasma (a)
and serum samples (b) from patients with various malgnancies
and benign diseases. Patients are divided into four groups: diges-
tive tract cancer (gastric, colorectal, pancreatic, liver, duodenal),
breast cancer, miscellaneous malignancies (lung, kidney and blad-
der) and benign diseases (gall stone dises and benign breast
disease). The 97.5% level of healthy blood donors is marked as a
dashed line.
EDAcFN in plasma and serwn ofcarcinoma patients
Figure 2a shows the distribution of EDAcFN in plasma
samples and Figure 2b in serum samples of patients with
various malignancies. More than half of all patients with
cancer (54%) had a plasma level of EDAcFN higher than the
97.5% level of normal subjects. Elevated plasma levels were
found in 79% of 43 patients with digestive tract cancer and
in 71% of 17 patients with miscellaneous malignancies, but
only in 30% of patients with breast cancer. The frequency of
elevated plasma EDAcFN concentrations in the various
disease subgroups studied is shown in Table I. The mean
concentration of EDAcFN in plasma samples of patients
with digestive tract cancer was 12.26 + 6.33 mg 1I (n =43
patients) and in patients with miscellaneous malignancies
11.12 ± 6.30 mg l-
1 (n = 17 patients). Both values were signi-
ficantly higher than the mean value in 479 controls (2.46 ±
1.99mg1-'). Median values were 11.58mg1-', 8.50mgl-l
and 3.49 mg 11 respectively. Iii patients with breast cancer,
the EDAcFN concentration in plasma was similar to that of
pregnant women (4.38 ± 3.97 mg 1', n =60 patients).
The mean concentration of EDAcFN in 43 serum samples
from patients with digestive tract cancer was 4.28 ± 3.84
mg -', in 17 samples obtained from patients with miscel-
laneous malignancies 5.18 ± 5.99 mg 1-' and in sera from 60
patients with breast cancer 2.01 ± 2.52 mg 1'. All mean
values were higher than that of healthy blood donors
(0.30 ± 0.51). The median values in sera of patients with
digestive tract, miscellaneous and breast cancer were
2.88mg1-', 2.10mg1-1 and 1.24mgl1- respectively.
In 72% of all patients with cancer, the EDAcFN level of
serum was higher than the 97.5% level of normal subjects.
Elevated serum levels were found in 86% of patients with
digestive tract cancer, in 76% of patients with miscellaneous
malignancies and in 60% of patients with breast cancer. The
frequency of elevated serum EDAcFN concentrations in the
various disease subgroups studied is shown in Table I.
Figure 3a shows the receiver operating curves (ROC) of
EDAcFN in serum and plasma from healthy blood donors
and cancer patients with digestive tract and miscellaneous
malignancies. Both curves behave similarly, but the true-
positive fraction, i.e. the sensitivity, was slightly higher for
plasma samples than for serum samples. However, in spite of
the higher concentrations of EDAcFN in plasma than in
serum, the true-positive fraction in patients with breast
cancer was significantly higher for serum (Figure 3b). Thus,
according to ROC analysis, EDAcFN seems to be a more
specific marker for malignancies other than breast cancer.
Western blotting ofFN by monoclonal antibodies
FNs isolated from equal amounts of plasma and serum of a
patient with gastrointestinal carcinoma and a healthy blood
donor were analysed by Western blotting. MAb BF12
reacted with all plasma and serum samples at a position of
about Mr 220 000, reacting most strongly with normal
human plasma. Western blotting with MAb DH1 demon-
strated the presence of the EDA-immunoreactive band. The
intensity of this band visually correlated with the levels of
EDAcFN measured by EIA, also showing higher overall
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Fgue 3 A comparison of EDAcFN in serum (-) and plasma
(-) from patients with digestive tract cancer and miscellaneous
malignancies (a) and breast cancer (b) using ROC analysis. The
control group consists of healthy blood donors.
concentrations of EDAcFN in plasma samples. Normal
serum content of EDAcFN was hardly visible. Consistent
with ETA results. Western transfer examination revealed an
increased concentration of EDAcFN in plasma and serum of
a cancer patient compared with healthy blood donors (Figure
4).
Numerous studies have evaluated whether FN levels in
plasma or other body fluids might be indicative of cancer or
other clinical conditions. The results have been contradictory.
High plasma levels of total FN have been reported in
patients with breast, ovarian, lung, pancreatic and colonic
carcinoma (Mosher and Williams, 1978; Parsons et al., 1979a,b;
Todd et al., 1980; Choate and Mosher, 1983), whereas
reduced levels of FN have been reported in plasma of
patients with lymphatic leukaemia (Bruhn and Heimburger,
1976) and haemopathic diseases (De Russe et al., 1985).
Interestingly, the latter diseases differ from carcinomas in
that they lack a stromal response. On the other hand, Eijan
et al. (1986) found no clear correlation between FN levels
and breast cancer, and normal FN concentrations have also
been reported in patients with acute leukaemia, lacking the
stromal response (Choate and Mosher, 1983). Moreover, the
FN level often increases in various benign conditions (Todd
et al., 1980). Accordingly, the clinical usefulness of total
plasma FN as a marker for cancer seems limited. Recently,
immunoassays measuring different fragments or isoforms of
FN have been evaluated in the diagnosis of benign and
malignant diseases. Katayama et al. (1991) have studied FN
fragments in urine as a tumour marker. Different isoforms of
FN, such as EDAcFN and oncofetal FN, have so far been
used as markers for other clinical conditions such as vascular
injury or acute pulmonary injury (Peters et al., 1988, 1989) or
as a predictor of preterm delivery (Lockwood et al., 1991).
Recently, we described an EIA detecting EDAcFN
(Ylatupa et al., 1993). In this study, the normal values of
EDAcFN in plasma and serum were determined by studying
blood donors. Low concentrations of EDAcFN were found
Fige 4 Western blot analysis of EDAcFN and total FN in
plasma and serum samples from a healthy blood donor and from
a patient with gastrointestinal carcinoma. Lanes 1-5, the MAb
DHI-reactive EDAcFN; lanes 6-9, BF12-reactive total FN. Lane
1, a purified standard cFN; lanes 2 and 6, serum of the car-
cinoma patient; lanes 3 and 7, plasma from the carcinoma
patient; lanes 4 and 8, plasma from a healthy blood donor; lanes
5 and 9, serum from a healthy blood donor.
in both plasma and serum of healthy individuals. The con-
centration in serum was clearly lower than in plasma, which
apparently is due to binding of FN to fibrin in blood clotting
(Engvall et al., 1978). It has previously been shown that the
levels of total FN in plasma increase significantly with age
and that there are minor differences in total FN concentra-
tions between men and women (Fyrand and Solumn, 1976;
Peters et al., 1989). However, the concentrations of EDAcFN
in serum and plasma seem to be independent of sex and age.
Our observations are in concordance with those of Peters et
al. (1989).
Immunohistochemically, a strong expression of EDAcFN
has been shown in malignant tumours using the monoclonal
antibody DHI against the EDA domain of cFN (Vartio et
al., 1987; Gould et al., 1990). In this study we performed a
preliminary evaluation of the potential utility of our new
assay as a plasma and/or serum tumour marker by determin-
ing the EDAcFN levels in 120 cancer patients. A majority of
patients with gastrointestinal cancers showed elevated values
in both plasma and serum. The same was true for a small
group of miscellaneous tumours, including lung, kidney,
liver, bladder and a few other cancers. In spite of the higher
concentrations found in plasma, the sensitivity of the test,
when the 97.5% level of blood donors were used as a cut-off
level, was similar in plasma and serum. In breast cancer,
however, there was a difference between plasma and serum.
Sixty per cent of the patients had an elevated serum level of
EDAcFN, whereas the concentration in plasma was low in
most patients. On the other hand, the elevated serum levels
in many breast cancer patients were only slightly above the
cut-off level, and in 30% of patients with benign diseases the
serum level exceeded the cut-off level. In plasma samples
from all patients with benign disease the concentration
remained below the cut-off level.
Since the levels of various tumour markers are often in-
creased during pregnancy, EDAcFN was measured in 20
plasma samples from pregnant women. The mean concentra-
tion was higher than that of healthy blood donors, but
remained clearly below the cut-off level of normal subjects.
Theoretically, plasma should be a more reliable medium
than serum for determining the level of EDAcFN in the
circulation, since the amount of FN lost in blood clotting is
unpredictable. Using ROC analysis, EDAcFN in serum
seems a more specific marker for breast cancer. However, for
malignancies other than breast cancer there was only a minor
difference between serum and plasma samples. The number
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of patients studied is, however, too small for definite con-
clusions to be drawn.
In conclusion, the results of the new EDAcFN EIA as a
tumour marker test are very encouragng, and a larger
number of patients with various ars, different stages of
cancer and benign diseases are now being collected for fur-
ther evaluation.
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